PSB-0739|cas:1052087-90-7|西域试剂

PSB-0739,98.67%

产品编号：Bellancom-108660| CAS NO：1052087-90-7| 分子式：C₂₆H₁₇N₃Na₂O₈S₂| 分子量：609.54

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-108660	￥1300.00	杭州北京（现货）
Bellancom-108660	￥2100.00	杭州北京（现货）
Bellancom-108660	￥4500.00	杭州北京（现货）
Bellancom-108660	￥7600.00	杭州北京（现货）
Bellancom-108660	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PSB-0739

产品介绍

PSB-0739 是一种高亲和力、竞争性、非选择性的血小板 P2Y₁₂ 受体拮抗剂，K_i 值为 24.9 nM。P2Y₁₂ 受体在血小板聚集中起着至关重要的作用。PSB-0739 具有抗血栓作用。

生物活性

PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y₁₂ receptor antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect.

体外研究

PSB-0739 is a potent competitive non-nucleotide antagonist at the human P2Y₁₂ receptor with a pA₂ value of 9.8.
PSB-0739 inhibits ADP-evoked Ca²⁺ responses with an EC₅₀ of 5.4±1.8 μM and causes a rightward parallel shift in the ADP concentration–response curve in THP-1 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	THP-1 monocytic cell line
Concentration:	10 nM, 100 nM, 1 μM, 10 μM
Incubation Time:
Result:	Attenuated ADP-evoked responses (IC₅₀=5.4±1.8 μM).

体内研究
(In Vivo)

PSB-0739 (0.01-0.3 mg/kg, intrathecally) has dose-dependent and significant antihyperalgesic effect in low doses. The minimal effective dose (mED) is 0.1 mg/kg^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats, 150-250 g, 6-8/group^[4]
Dosage:	0.01, 0.03, 0.1, 0.3 mg/kg
Administration:	Intrathecal injection ( i.t.)
Result:	Displayed a dose-dependent inhibitory effect on mechanical hyperalgesia in the range of 0.01–0.1 mg/kg.

体内研究

PSB-0739 (0.01-0.3 mg/kg, intrathecally) has dose-dependent and significant antihyperalgesic effect in low doses. The minimal effective dose (mED) is 0.1 mg/kg^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats, 150-250 g, 6-8/group^[4]
Dosage:	0.01, 0.03, 0.1, 0.3 mg/kg
Administration:	Intrathecal injection ( i.t.)
Result:	Displayed a dose-dependent inhibitory effect on mechanical hyperalgesia in the range of 0.01–0.1 mg/kg.

体内研究

PSB-0739 (0.01-0.3 mg/kg, intrathecally) has dose-dependent and significant antihyperalgesic effect in low doses. The minimal effective dose (mED) is 0.1 mg/kg^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats, 150-250 g, 6-8/group^[4]
Dosage:	0.01, 0.03, 0.1, 0.3 mg/kg
Administration:	Intrathecal injection ( i.t.)
Result:	Displayed a dose-dependent inhibitory effect on mechanical hyperalgesia in the range of 0.01–0.1 mg/kg.